2 results
Approved WMOCompleted
* Primary objective: To determine the effect of 78-weeks therapy with omalizumab compared to placebo on the number of sub-epithelial eosinophils, a marker of airway inflammation, in patients with persistent moderate to severe allergic asthma. *…
Approved WMOCompleted
To determine the relative bioavailability of pramipexole 4.5 mg tablets vs. 4.5 mg Sifrol in healthy subjects after up-titration.